These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24980841)

  • 1. Blood safety: Opportunities and challenges addressed through Critical Path research at FDA.
    Atreya CD; Epstein JS
    Drug Discov Today Technol; 2007; 4(2):51-4. PubMed ID: 24980841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How the Critical Path Initiative Addresses CDER's Regulatory Science Needs: Some Illustrative Examples.
    Geanacopoulos M; Barratt R
    Ther Innov Regul Sci; 2015 Jul; 49(4):466-472. PubMed ID: 30222436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interview with Janet Woodcock: progress on the FDA's critical path initiative.
    Woodcock J
    Biomark Med; 2009 Dec; 3(6):671-3. PubMed ID: 20477704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomedical applications of tissue engineering technology: regulatory issues.
    Hellman KB
    Tissue Eng; 1995; 1(2):203-10. PubMed ID: 19877928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feeding the preterm infant: opportunities and challenges of bringing science to the bedside.
    Neu J; Bradley CL; Ding ZY; Tucker HN; Berseth CL
    J Pediatr; 2013 Mar; 162(3 Suppl):S101-6. PubMed ID: 23445840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug eluting stents and the critical path initiative: Evolving paradigms for safety evaluation.
    Sanhai WR; Stockbridge N; Fiorentino RP; Uchida T; Uhl K; Krucoff MW
    Drug Discov Today Technol; 2007; 4(2):43-6. PubMed ID: 24980839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of the Food and Drug Administration Electrocardiogram Warehouse: a paradigm for the critical pathway initiative.
    Cabell CH; Noto TC; Krucoff MW
    J Electrocardiol; 2005 Oct; 38(4 Suppl):175-9. PubMed ID: 16226096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development.
    Karsdal MA; Henriksen K; Leeming DJ; Mitchell P; Duffin K; Barascuk N; Klickstein L; Aggarwal P; Nemirovskiy O; Byrjalsen I; Qvist P; Bay-Jensen AC; Dam EB; Madsen SH; Christiansen C
    Biomarkers; 2009 May; 14(3):181-202. PubMed ID: 19399662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Missing data issues at the FDA Center for Biologics Evaluation and Research.
    Scott JA; Hsu H
    J Biopharm Stat; 2011 Mar; 21(2):196-201. PubMed ID: 21390996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Search for shortcuts on the critical path to market: US FDA perspectives from the diagnostic side.
    Gutman S; Hackett J
    Pharmacogenomics; 2006 Dec; 7(8):1223-7. PubMed ID: 17184209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A global regulatory science agenda for vaccines.
    Elmgren L; Li X; Wilson C; Ball R; Wang J; Cichutek K; Pfleiderer M; Kato A; Cavaleri M; Southern J; Jivapaisarnpong T; Minor P; Griffiths E; Sohn Y; Wood D
    Vaccine; 2013 Apr; 31 Suppl 2():B163-75. PubMed ID: 23598478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paving the critical path: how can clinical pharmacology help achieve the vision?
    Lesko LJ
    Clin Pharmacol Ther; 2007 Feb; 81(2):170-7. PubMed ID: 17259944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA and the critical path to twenty-first-century medicine.
    Pitts PJ
    J Med Philos; 2008 Oct; 33(5):515-23. PubMed ID: 18840855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interview with Janet Woodcock.
    Woodcock J
    Bioanalysis; 2010 Sep; 2(9):1535-8. PubMed ID: 21083281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Building a roadmap to biomarker qualification: challenges and opportunities.
    Amur SG; Sanyal S; Chakravarty AG; Noone MH; Kaiser J; McCune S; Buckman-Garner SY
    Biomark Med; 2015; 9(11):1095-105. PubMed ID: 26526897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new collaborative path in medical device development: the medical device innovation consortium.
    Kampfrath T; Cotten SW
    Clin Biochem; 2013 Oct; 46(15):1320-2. PubMed ID: 23578741
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.